Position paper on CDK4/6 inhibitors in early breast cancer

被引：1

作者：

Gnant, Michael ^{[1
]}

Singer, Christian F. ^{[2
]}

Rinnerthaler, Gabriel ^{[3
]}

Pfeiler, Georg ^{[2
]}

Egle, Daniel ^{[4
]}

Balic, Marija ^{[5
]}

Bartsch, Rupert ^{[6
]}

机构：

[1] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

[2] Med Univ Vienna, Dept Gynecol & Gynecol Oncol, Vienna, Austria

[3] Paracelsus Med Univ Salzburg, Oncol Ctr, Dept Internal Med 3, Haematol Med Oncol Haemostaseol Infectiol & Rheuma, A-5020 Salzburg, Austria

[4] Med Univ Innsbruck, Breast Canc Ctr Tirol, Dept Gynecol, Innsbruck, Austria

[5] Med Univ Graz, Dept Internal Med, Div Clin Oncol, Graz, Austria

[6] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2023年 / 16卷 / 02期

关键词：

Breast cancer; Adjuvant therapy; Cell cycle inhibitors; CDK4; 6; inhibitors; RIBOCICLIB PLUS LETROZOLE; THYMIDINE KINASE-ACTIVITY; ENDOCRINE THERAPY; NEOADJUVANT PALBOCICLIB; MOLECULAR PORTRAITS; INTRINSIC SUBTYPES; OPEN-LABEL; MULTICENTER; RESISTANCE; SIGNATURE;

D O I：

10.1007/s12254-023-00878-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.

引用

页码：135 / 144

页数：10

共 50 条

[31] CDK4/6 inhibitors
不详
CHEMICAL & ENGINEERING NEWS, 2016, : 30 - 31
[32] Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Carausu, Marcela
Neven, Patrick
Ignatiadis, Michail
ANNALS OF ONCOLOGY, 2025, 36 (02) : 127 - 129
[33] CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Haslam, Alyson
Ranganathan, Sruthi
Prasad, Vinay
Olivier, Timothee
EUROPEAN JOURNAL OF CANCER, 2024, 207
[34] Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer
Cunningham, Niamh C.
Turner, Nicholas C.
CANCER CELL, 2021, 39 (03) : 307 - 309
[35] First clinical experience with CDK4/6 inhibitors in breast cancer therapy
Cobec, Ionut Marcel
Moleriu, Lavinia
Moatar, Aurica Elisabeta
Rempen, Andreas
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (05)
[36] SBRT with CDK4/6 inhibitors for oligorecurrent/oligoprogressive breast cancer patients
Ippolito, E.
Onorati, E.
Greco, C.
Fiore, M.
Silipigni, S.
Matteucci, P.
Cerasani, L.
Carrafiello, S.
Palumbo, V.
Ramella, S.
RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S1298 - S1298
[37] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
Shen, Mimi
Ma, Zhiyuan
Zhu, Jiaxing
Wen, Guorong
Jin, Hai
An, Jiaxing
Tuo, Biguang
Liu, Xuemei
Li, Taolang
BIOORGANIC CHEMISTRY, 2025, 154
[38] Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Barroso-Sousa, Romualdo
Shapiro, Geoffrey I.
Tolaney, Sara M.
BREAST CARE, 2016, 11 (03) : 167 - 173
[39] The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, Ines
Abreu, Catarina
Costa, Luis
Casimiro, Sandra
CANCERS, 2023, 15 (19)
[40] Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
Echavarria, Isabel
Jerez, Yolanda
Martin, Miguel
Lopez-Tarruella, Sara
BREAST CARE, 2017, 12 (05) : 296 - 302

← 1 2 3 4 5 →